Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neu… Read more
Euroespes S.A. (EEP) - Net Assets
Latest net assets as of December 2022: €6.20 Million EUR
Based on the latest financial reports, Euroespes S.A. (EEP) has net assets worth €6.20 Million EUR as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.42 Million) and total liabilities (€5.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.20 Million |
| % of Total Assets | 54.29% |
| Annual Growth Rate | -3.08% |
| 5-Year Change | -65.45% |
| 10-Year Change | -16.59% |
| Growth Volatility | 36.5 |
Euroespes S.A. - Net Assets Trend (2010–2024)
This chart illustrates how Euroespes S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Euroespes S.A. (2010–2024)
The table below shows the annual net assets of Euroespes S.A. from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.57 Million | -11.08% |
| 2023-12-31 | €2.89 Million | -53.37% |
| 2022-12-31 | €6.20 Million | -16.53% |
| 2021-12-31 | €7.43 Million | -0.17% |
| 2020-12-31 | €7.44 Million | -0.13% |
| 2019-12-31 | €7.45 Million | -15.33% |
| 2018-12-31 | €8.80 Million | +92.66% |
| 2017-12-31 | €4.57 Million | +7.11% |
| 2016-12-31 | €4.26 Million | +38.35% |
| 2015-12-31 | €3.08 Million | +12.25% |
| 2014-12-31 | €2.75 Million | -31.09% |
| 2010-12-31 | €3.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Euroespes S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 150.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.89 Million | 112.57% |
| Total Equity | €2.57 Million | 100.00% |
Euroespes S.A. Competitors by Market Cap
The table below lists competitors of Euroespes S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAFRAN (SEJ1.SG)
STU:SEJ1
|
$3.02 Million |
|
ChargePanel AB
ST:CHARGE
|
$3.02 Million |
|
Royale Energy Inc
OTCQB:ROYL
|
$3.02 Million |
|
LONGTU KOREA Inc
KQ:060240
|
$3.02 Million |
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
$3.02 Million |
|
FCW Holdings Bhd
KLSE:2755
|
$3.02 Million |
|
ROCKWELL AUTOMATION (RWL.SG)
STU:RWL
|
$3.02 Million |
|
Telefonica Chile S.A.
SN:CTC
|
$3.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Euroespes S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,890,601 to 2,570,455, a change of -320,146 (-11.1%).
- Net loss of 323,179 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-323.18K | -12.57% |
| Other Changes | €3.03K | +0.12% |
| Total Change | €- | -11.08% |
Book Value vs Market Value Analysis
This analysis compares Euroespes S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.44x to 1.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.78 | €0.34 | x |
| 2018-12-31 | €0.80 | €0.34 | x |
| 2019-12-31 | €0.68 | €0.34 | x |
| 2020-12-31 | €0.64 | €0.34 | x |
| 2021-12-31 | €0.64 | €0.34 | x |
| 2022-12-31 | €0.53 | €0.34 | x |
| 2023-12-31 | €0.25 | €0.34 | x |
| 2024-12-31 | €0.22 | €0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Euroespes S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.11%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.70x
- Recent ROE (-12.57%) is below the historical average (-8.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 2.19% | 2.62% | 0.65x | 1.28x | €-311.05K |
| 2014 | 6.52% | 7.15% | 0.39x | 2.31x | €-95.59K |
| 2015 | 6.72% | 7.25% | 0.42x | 2.18x | €-100.95K |
| 2016 | 9.01% | 13.55% | 0.28x | 2.34x | €-37.66K |
| 2017 | 2.57% | 4.06% | 0.28x | 2.28x | €-304.53K |
| 2018 | -3.02% | -9.98% | 0.20x | 1.52x | €-1.10 Million |
| 2019 | -17.62% | -52.98% | 0.21x | 1.59x | €-1.97 Million |
| 2020 | -5.53% | -16.30% | 0.22x | 1.57x | €-1.16 Million |
| 2021 | -2.47% | -5.57% | 0.27x | 1.65x | €-926.18K |
| 2022 | -18.34% | -34.47% | 0.29x | 1.84x | €-1.76 Million |
| 2023 | -73.83% | -72.25% | 0.37x | 2.74x | €-2.42 Million |
| 2024 | -12.57% | -11.11% | 0.42x | 2.70x | €-580.22K |
Industry Comparison
This section compares Euroespes S.A.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $50,093,170
- Average return on equity (ROE) among peers: 22.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Euroespes S.A. (EEP) | €6.20 Million | 2.19% | 0.84x | $3.02 Million |
| Clinica Baviera (CBAV) | $98.36 Million | 40.88% | 1.15x | $110.76 Million |
| Pangaea Oncology S.A. (PANG) | $1.83 Million | 4.24% | 2.58x | $13.97 Million |